NOX5 and rheumatoid arthritis: This imbalance was associated with impaired NOX5-dependent ROS production in PsA Mo-DC treated with Tofacitinib (Figure 5B, p < 0.001), which was observed also in HC (Supplementary Figure 4B), whereas a lack of response to Ionomycin was observed in RA cells, leading to a limited effect of Tofacitinib (Figure 5B).